Drug Type Small molecule drug |
Synonyms Hepenax, L-ornithine L-aspartate, L-ORNITHINE L-ASPARTATE GRANULES + [6] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Germany (01 Jan 1969), |
Regulation- |
Molecular FormulaC9H19N3O6 |
InChIKeyIXUZXIMQZIMPSQ-ZBRNBAAYSA-N |
CAS Registry3230-94-2 |
Start Date15 Jun 2026 |
Sponsor / Collaborator |
Start Date25 Sep 2025 |
Sponsor / Collaborator |
Start Date24 Jun 2025 |
Sponsor / Collaborator |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08303 | Ornithine aspartate | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hyperammonemia | China | 04 Aug 2000 | |
| Hepatic Encephalopathy | Germany | 01 Jan 1969 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 4 | 52 | (liver cirrhosis + hepatic encephalopathy grade 0-2) | uinlsjcayr(ngkwynnaxa) = decreased ydeshrtlzo (gsgdvfflgt ) View more | Positive | 01 Jan 2026 | ||
Not Applicable | Hepatic Encephalopathy serum ammonia levels | 40 | IV L-Ornithine-L-Aspartate (LOLA) | fnkmwqdihp(xmevprercg) = vwspuutgct nwpvewhnrk (cvrylksnka, 32.58) | Positive | 15 Oct 2023 | |
Oral L-Ornithine-L-Aspartate (LOLA) | fnkmwqdihp(xmevprercg) = qdssivqgtw nwpvewhnrk (cvrylksnka, 13.82) | ||||||
Phase 2 | 201 | Placebo | bydfcizhbw(szouzujanq) = dbyoikbfep qfmyphxkpe (tjoxxbcgyz ) | Negative | 01 Jun 2009 | ||
bydfcizhbw(szouzujanq) = iggqlpjnsb qfmyphxkpe (tjoxxbcgyz ) |








